From: Individualised treatment targets in patients with type-2 diabetes and hypertension
Multivariable OR (95% CI) | |
---|---|
Age > median | |
Yes vs. no | 1.25 (1.07–1.45) |
Female gender | |
Yes vs. no | 1.03 (0.91–1.17) |
Diabetes duration > median | |
Yes vs. no | 0.65 (0.58–0.73) |
Bodyweight > median | |
Yes vs. no | 0.91 (0.80–1.02) |
HbA1c treatment target | |
> 7.0% vs. ≤ 6.5% | 3.02 (2.61–3.49) |
> 6.5 to ≤ 7.0% vs. ≤ 6.5% | 5.31 (4.38–6.44) |
HbA1c baseline tertile | |
3rd tertile vs. 1st tertile | 0.25 (0.22–0.30) |
2nd tertile vs. 1st tertile | 0.15 (0.13–0.18) |
Care-dependent | |
Yes vs. no | 0.84 (0.57–1.24) |
Not working | |
Yes vs. no | 0.97 (0.83–1.14) |
< 9 years of school education | |
Yes vs. no | 0.86 (0.76–0.98) |
Patient lives alone | |
Yes vs. no | 0.88 (0.77–1.02) |
< 1 h per week of physical activity | |
Yes vs. no | 0.93 (0.82–1.06) |
Any vascular diseasea | |
Yes vs. no | 0.96 (0.84–1.09) |
Any diabetes related diseaseb | |
Yes vs. no | 1.04 (0.90–1.20) |
Other concomitant disease | |
Yes vs. no | 0.94 (0.84–1.06) |
All lipid values available (< 6 weeks)c | |
Yes vs. no | 1.03 (0.90–1.18) |
All BG values available (< 6 weeks)d | |
Yes vs. no | 1.29 (1.14–1.45) |
All renal lab values availablee | |
Yes vs. no | 1.24 (1.09–1.41) |
≥ 3 oral antidiabetic drugs at BL | |
Yes vs. no | 0.59 (0.49–0.72) |
People receiving any insulin | |
Yes vs. no | 0.82 (0.70–0.97) |
≥3 antihypertensive drugs at BL | |
Yes vs. no | 1.07 (0.95–1.21) |
Any non-severe hypoglycaemiaf | |
Yes vs. no | 0.95 (0.74–1.23) |
Any severe hypoglycaemiag | |
Yes vs. no | 0.53 (0.25–1.13) |